Diabetes & Endocrinology
Latest news
532 articles · 20 / page
Recent Advances in Cinnamon and Its Extracts: Clinical Applications and Therapeutic Potentials Across Metabolic, Cardiovascular, Cognitive, and Infectious Diseases
A decade of research highlights cinnamon’s benefits in glycemic control, lipid modulation, anti-inflammatory effects, cognitive enhancement, and antimicrobial activity, supporting its adjunctive clinical use and revealing promising therapeu
Sulforaphane in Clinical Medicine: A Decade of Research Progress and Therapeutic Potential
This review synthesizes 10 years of sulforaphane (SFN) research, highlighting its pharmacology, clinical trial outcomes, and emerging therapeutic prospects across cancer, metabolic, renal, neurodevelopmental, and cardiovascular disorders.
Recent Advances in Dihydroberberine Research: Pharmacokinetics, Mechanisms, and Clinical Potential
This review synthesizes the latest 5-year evidence on dihydroberberine, highlighting improved bioavailability over berberine, mechanistic insights from metabolic and network pharmacology studies, and its promising clinical applications in m
Berberine Ursodeoxycholate (HTD1801): A Promising Oral Therapy for Type 2 Diabetes with Multifaceted Metabolic Benefits
A phase 2 randomized trial shows berberine ursodeoxycholate (HTD1801) significantly reduces HbA1c and improves liver and cardiometabolic parameters in type 2 diabetes patients inadequately controlled with diet and exercise, with a favorable
HTD1801 Shows Promising Histologic Improvement in Metabolic Dysfunction-Associated Steatohepatitis: Insights from Preclinical and Phase 2 Clinical Studies
HTD1801 (berberine ursodeoxycholate) significantly improves liver histology and reduces fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) as demonstrated by preclinical models and a Phase 2 trial.
Berberine and Cinnamon Synergy: A Promising Adjunct Therapy for Improving Glycemic Control and LDL Cholesterol in Type 2 Diabetes
A 12-week randomized controlled trial demonstrated that supplementation with berberine plus cinnamon significantly lowers fasting blood sugar, HbA1c, and LDL cholesterol in patients with type 2 diabetes, offering potential for improved card
Preventive PCI for Vulnerable Non-Flow-Limiting Coronary Plaques in Diabetes: Insights from the PREVENT Trial
The PREVENT trial demonstrates that preventive PCI reduces adverse cardiac events in patients with vulnerable, non-flow-limiting coronary plaques, regardless of diabetes status, supporting a proactive interventional strategy alongside medic
SADI-S vs RYGB for Obesity: Superior Weight Loss and Comparable Safety at 2 Years from the French SADISLEEVE Trial
A French multicentre trial showed single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) achieved superior weight loss compared to Roux-en-Y gastric bypass (RYGB) at 2 years, with similar safety profiles.
Evolocumab’s Impact on Cardiovascular Risk in Type 1 Diabetes: Insights from the FOURIER Trial
The FOURIER trial reveals intensive LDL-C lowering with evolocumab substantially reduces cardiovascular events in type 1 diabetes patients with ASCVD, highlighting significant clinical benefit and urging further dedicated research.
Long-Term Kidney Protection with SGLT2 Inhibitors in Type 2 Diabetes and CKD: Insights from the DARWIN-Renal Study
A large real-world study shows that SGLT2 inhibitors significantly slow kidney function decline and improve albuminuria compared with other glucose-lowering drugs in type 2 diabetes patients with chronic kidney disease.
Enhancing Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes: Insights from Dapagliflozin and Exenatide Combination Therapy
Dapagliflozin and exenatide independently improve beta-cell function and insulin sensitivity in type 2 diabetes; their combination markedly enhances these effects, suggesting superior glycemic control potential.
Predictive Factors for Diabetes Outcomes One Year After Total Pancreatectomy with Islet Autotransplantation: Insights from a Large Multicenter Study
This multicenter study identifies key predictors of diabetes outcomes one year after total pancreatectomy with islet autotransplantation, highlighting the importance of preoperative glycemic control and age in achieving insulin independence
What’s New in Diabetes Care 2024: Key Recommendations from the ADA Standards of Care
A practical, clinician-friendly summary of the American Diabetes Association’s 2024 Standards of Care, highlighting new recommendations on GLP-1/GIP therapy, SGLT2 inhibitors, continuous glucose monitoring, and individualized care.
ADA Standards of Care 2024: A Clinician-Friendly Guide to the New Cardiorenal‑Metabolic Era in Diabetes Care
The ADA’s 2024 Standards refocus diabetes care around cardiorenal protection, expanded use of GLP‑1 and SGLT2 therapies, wider adoption of glucose‑sensing technology, and integrated obesity management.
Untangling Adiposity and Insulin Resistance in HFpEF: Clarifying Their Distinct Impact on Cardiac Function
This study reveals that excess adiposity, rather than insulin resistance or diabetes, predominantly drives left heart abnormalities and elevated pulmonary pressures in HFpEF, highlighting the need for targeted cardiometabolic therapies beyo
Adjunct-to-Insulin Therapy Using SGLT2 Inhibitors in Youth with Type 1 Diabetes: Clinical Impact and Renal Outcomes
SGLT2 inhibitors adjunct to insulin improve glycemic control, reduce hyperfiltration, and are generally safe in youth with type 1 diabetes under careful ketone monitoring and DKA risk mitigation.
Revealing Metabolic Subtypes in Gestational Diabetes Using Dynamic OGTT-Derived C-Peptide Trajectories: Implications for Personalized Risk and Management
Dynamic C-peptide patterns during OGTT uncover metabolic heterogeneity in GDM, identifying insulin-resistant women at risk for fetal overgrowth and normoglycemic women at risk for preeclampsia, suggesting improved stratified treatment beyon
Harnessing Digital Therapeutics to Improve Glycemic Control in Type 2 Diabetes: Insights from the BRIGHT Trial
The BRIGHT trial evaluates AspyreRx, a digital cognitive behavioral therapy, for enhancing glycemic control in type 2 diabetes patients with residual hyperglycemia on stable medical therapy, focusing on efficacy, safety, and real-world appl
Clinical Therapeutic Value of Curcumin Supplementation in Cardiovascular Disease, Diabetes, Cognitive Function, Aging, and Neurodegenerative Disorders: A Synthesis of Recent Evidence
Current evidence supports curcumin supplementation for reducing cardiovascular risk factors and preventing type 2 diabetes progression, with emerging potential in cognitive decline and aging-related degenerative diseases.
Protective Effects of High-Intensity Interval Training on Cardiovascular, Neurological, and Metabolic Health: An Evidence-Based Review
This review synthesizes recent evidence demonstrating that high-intensity interval training (HIIT) confers cardiometabolic benefits, modulates microvascular and neural function, enhances insulin sensitivity, and improves mental health outco
Browse by specialty
Open language-specific specialty feeds and department pages.